LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
NRXS
NeurAxis, Inc.
There isn't enough reported data to score NRXS yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NRXS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
NRXS's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NRXS PE Valuation
NRXS has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NRXS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect NRXS's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over NRXS on earnings quality, reporting a profit while its opponent remains loss making.
NRXS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.05 | -$0.03 |
| Q2 2026 | -$0.77 | +$0.26 |
| Q1 2026 | -$0.80 | +$0.43 |
| Q4 2025 | -$0.95 | +$0.27 |
| Q3 2023 | -$2.91 | -$2.22 |
NRXS is still losing money, but far less than before: $1.05 per share over the past year, against $2.91 at its worst in late 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over NRXS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NRXS on profitability, with a higher operating margin.
NRXS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2M | +150% |
| Q2 2026 | $1.9M | +116% |
| Q1 2026 | $1.6M | +80% |
| Q4 2025 | $968.1K | +27% |
| Q3 2025 | $811.4K | +22% |
| Q2 2025 | $894.1K | +46% |
| Q1 2025 | $895.7K | +39% |
| Q4 2024 | $761.2K | +43% |
NRXS's revenue has grown year over year for nine quarters in a row: $2M last quarter, up 150% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -324% | -66 points |
| Q2 2026 | -110% | +82 points |
| Q1 2026 | -108% | +148 points |
| Q4 2025 | -177% | +15 points |
| Q3 2025 | -259% | -11 points |
| Q2 2025 | -192% | +169 points |
| Q1 2025 | -256% | +27 points |
| Q4 2024 | -193% | +113 points |
NRXS's operating margin was −324% last quarter, down 66 points from the same quarter a year ago, near the bottom of its range since 2021.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with NRXS at down 27%.
NRXS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.3M | -$840.8K |
| Q4 2025 | -$1.9M | -$181.9K |
| Q3 2025 | -$1.4M | -$30.4K |
| Q2 2025 | -$1.5M | +$149K |
| Q1 2025 | -$1.6M | -$274.8K |
| Q4 2024 | -$1.8M | +$887.4K |
| Q3 2024 | -$1.4M | +$1.4M |
| Q1 2024 | -$1.3M | -$716.4K |
NRXS has burned cash in almost every quarter: −$7M over the past year, against −$6M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NRXS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NRXS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.1% | +865K shares |
| 1 year | +31% | +3.1M shares |
| 3 years | +548% | +11M shares |
NRXS has 13M diluted shares, up 31% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NRXS Net Leverage
NRXS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NRXS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.3 | Neutral |
| Stochastic | 38.7 | Neutral |
NRXS's weekly RSI is 42 (neutral) and its Stochastic is 39 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NRXS PE vs Healthcare Sector
NRXS has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has stronger trend alignment. LLY is above 5 of 5 weekly averages versus NRXS above 1 of 4.
NRXS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.98 | 18% below |
| 20 week MA | $6.73 | 15% below |
| 50 week MA | $6.28 | 8.4% below |
| 100 week MA | $4.39 | 31% above |
NRXS has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 31% above its 100-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
NRXS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $6.15 | $2.67 | -57% |
| 2024 | $2.67 | $2.43 | -9% |
| 2025 | $2.43 | $3.92 | +61% |
| 2026 YTD | $3.92 | $5.75 | +47% |
NRXS has the edge over LLY on returns for 2026, with the stronger performance.